These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 606425)

  • 21. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Junor BJ; Catto GR; Macleod M
    Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512
    [No Abstract]   [Full Text] [Related]  

  • 22. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
    Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
    [No Abstract]   [Full Text] [Related]  

  • 23. Spinal calcium changes with 1alpha-hydroxyvitamin D3.
    Dabek JT; Robinson BH; Naik RB; Al-Hiti K
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():147s-150s. PubMed ID: 606412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole-body in-vivo neutron activation analysis in assessing treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Naik RB; Gosling P; Price CP; Robinson BH; Dabek JT; Heath DA; James HM; Kanis JA; Smith R
    Br Med J; 1976 Jul; 2(6027):79-83. PubMed ID: 1276820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term experience of alfacalcidol in renal osteodystrophy.
    Sharman VL; Brownjohn AM; Goodwin FJ; Hately W; Manning RM; O'Riordan JH; Papapoulos SE; Marsh FP
    Q J Med; 1982; 51(203):271-8. PubMed ID: 7146311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Renal osteodystrophy in two children : a comparison of the effects of 1 alpha-hydroxycholecalciferol (author's transl)].
    Chantraine JM; Davin JC; Lambrechts L; Heynen G
    Ann Endocrinol (Paris); 1979; 40(2):161-2. PubMed ID: 475307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy.
    Gotloib L; Mines M; Mazur Y; Sklan D; Garmizo AL; Jancu J; Israeli M; Malul M
    Isr J Med Sci; 1978 Jul; 14(7):731-5. PubMed ID: 681163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of senile osteoporosis with 1alpha-hydroxyvitamin D3.
    Sørensen OH; Andersen RB; Christensen MS; Friis T; Hjorth L; Jørgensen FS; Lund B; Melsen F; Mosekilde L
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():169s-175s. PubMed ID: 342143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency.
    Pietrek J; Kokot F; Kuska J
    Int Urol Nephrol; 1978; 10(2):153-60. PubMed ID: 700946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1alpha-hydroxycholecalciferol. Long-term treatment of patients with uraemic osteodystrophy.
    Nielsen SP; Binderup E; Godtfredsen WO; Jensen H; Ladefoged J
    Nephron; 1976; 16(5):359-70. PubMed ID: 1264309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal osteodystrophy in early chronic renal failure.
    Suzuki M; Hirasawa Y
    Contrib Nephrol; 1980; 22():28-38. PubMed ID: 7398337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure.
    Witmer G; Margolis A; Fontaine O; Fritsch J; Lenoir G; Broyer M; Balsan S
    Kidney Int; 1976 Nov; 10(5):395-408. PubMed ID: 794558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy.
    Ahmed KY; Varghese Z; Wills MR; Meinhard EA; Moorhead JF
    Lancet; 1978 Mar; 1(8065):629-32. PubMed ID: 76168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.
    Brickman AS; Sherrard DJ; Jowsey J; Singer FR; Baylink DJ; Maloney N; Massry SG; Norman AW; Coburn JW
    Arch Intern Med; 1974 Nov; 134(5):883-8. PubMed ID: 4613310
    [No Abstract]   [Full Text] [Related]  

  • 36. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 37. [Immunoreactive parathyroid hormone, 25-hydroxycalciferol and bone histology in renal osteodystrophy (author's transl)].
    Offermann G; Schaefer K; Schulz A; Delling G
    Klin Wochenschr; 1976 Jul; 54(13):625-32. PubMed ID: 940299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
    Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
    Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Renal osteodystrophy: the importance of 1-alpha-OH-D3].
    Berland Y; Olmer M; Grandvuillemin M; Lachaize AM
    Sem Hop; 1981 Mar 8-15; 57(9-10):445-9. PubMed ID: 6261385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iliac bone marrow mast cells in relation to the renal osteodystrophy of patients treated by haemodialysis.
    Ellis HA; Peart KM
    J Clin Pathol; 1976 Jun; 29(6):502-16. PubMed ID: 939806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.